We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$1.64B
AUM Growth
+$102M
Cap. Flow
-$45.8M
Cap. Flow %
-2.79%
Top 10 Hldgs %
45.39%
Holding
76
New
16
Increased
22
Reduced
20
Closed
12

Top Buys

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$54.8M
2
CNC icon
Centene
CNC
+$30.1M
3
ARRY
Array Biopharma Inc
ARRY
+$27.2M
4
EW icon
Edwards Lifesciences
EW
+$23.9M
5
ELGX
Endologix Inc
ELGX
+$21.5M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$48.4M
2
INCY icon
Incyte
INCY
+$41.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$29.9M
4
IMMU
Immunomedics Inc
IMMU
+$21.9M
5
PTHN
Patheon N.V.
PTHN
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Financials 1.4%
3 Communication Services 0.69%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$135M 8.2%
16,093,786
+3,327,924
+26% +$27.2M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$121M 7.38%
12,043,932
+668,080
+6% +$5.38M
PEN icon
3
Penumbra
PEN
$12.5B
$81.7M 4.98%
931,444
-102,964
-10% -$8.75M
PBYI icon
4
Puma Biotechnology
PBYI
$422M
$75.2M 4.58%
860,456
-864,958
-50% -$48.4M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$71.6M 4.36%
764,389
-208,307
-21% -$12.7M
JUNO
6
DELISTED
Juno Therapeutics, Inc.
JUNO
$66.3M 4.04%
+2,219,616
New +$54.8M
MOH icon
7
Molina Healthcare
MOH
$12B
$57.3M 3.49%
828,574
-321,153
-28% -$19.7M
SYNH
8
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$49.2M 3%
841,418
+207,639
+33% +$10.8M
GWPH
9
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$44.6M 2.72%
444,936
+112,392
+34% +$12.1M
ELV icon
10
Elevance Health
ELV
$82.9B
$43.6M 2.66%
231,886
+56,558
+32% +$10.2M
WVE icon
11
Wave Life Sciences
WVE
$1.1B
$41.4M 2.52%
2,224,407
+953,310
+75% +$20.5M
ATRA icon
12
Atara Biotherapeutics
ATRA
$74.7M
$38.3M 2.33%
109,362
-3
-0% -$1.16K
IMGN
13
DELISTED
Immunogen Inc
IMGN
$37.1M 2.26%
5,212,736
+1,228,002
+31% +$5.62M
OXFD
14
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$36.3M 2.21%
2,155,949
+151,100
+8% +$2.26M
AGIO icon
15
Agios Pharmaceuticals
AGIO
$2.38B
$35M 2.13%
681,165
-221,413
-25% -$11.3M
SGEN
16
DELISTED
Seagen Inc. Common Stock
SGEN
$34.4M 2.09%
665,139
-31,247
-4% -$1.99M
RGNX icon
17
Regenxbio
RGNX
$557M
$33.9M 2.07%
1,718,671
+449,540
+35% +$8.7M
CNC icon
18
Centene
CNC
$32.5B
$31.8M 1.94%
+796,400
New +$30.1M
ELGX
19
DELISTED
Endologix Inc
ELGX
$30.9M 1.88%
636,830
+365,091
+134% +$21.5M
BSX icon
20
Boston Scientific
BSX
$65.1B
$30.4M 1.85%
1,094,983
-105,116
-9% -$2.79M
BOLD
21
DELISTED
Audentes Therapeutics, Inc
BOLD
$27.9M 1.7%
1,459,616
+638,780
+78% +$10.2M
PRTA icon
22
Prothena Corp
PRTA
$454M
$27.6M 1.68%
509,698
-339,785
-40% -$18.1M
EW icon
23
Edwards Lifesciences
EW
$48.9B
$25.8M 1.57%
+654,000
New +$23.9M
ALDR
24
DELISTED
Alder Biopharmaceuticals
ALDR
$25.5M 1.55%
2,223,811
+313,925
+16% +$5.8M
XNCR icon
25
Xencor
XNCR
$1.39B
$25.1M 1.53%
1,187,494
-405,032
-25% -$9.08M
1
2 3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q2 2017 Portfolio in Review

As of Q2 2017, Redmile Group held 76 positions worth $1.64B, up 6.6% from $1.54B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Redmile Group's Q2 2017 filing shows 16 new, 22 increased, 20 reduced and 12 closed positions. Its largest new stake was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M. The largest sale was Puma Biotechnology, an estimated $48.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

  • Redmile Group's largest Q2 2017 buy was Juno Therapeutics, Inc.: 2,219,616 shares worth $66.3M.
  • Redmile Group added most to Array Biopharma Inc in Q2 2017, an estimated $27.2M increase.
  • Redmile Group's biggest Q2 2017 reduction was Puma Biotechnology, cutting an estimated $48.4M.
  • Redmile Group fully exited Incyte in Q2 2017, selling an estimated $41.1M.
  • Redmile Group's ten largest holdings make up 45% of its $1.64B portfolio in Q2 2017.
  • Redmile Group opened 16 new positions and closed 12 in Q2 2017.
  • Redmile Group's portfolio value rose 6.6% quarter-over-quarter to $1.64B.

Based on Redmile Group's 13F filing for Q2 2017, filed 15 Aug 2017.